A Collaborative Model for Endpoint Development for Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia

Two important diseases in need of new antibacterial drugs are acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneu-monia (CABP). These are common infec-tions in the United States, with millions of patients treated annually. The identifica-tion of well-defined and reliable efficacy outcome measures for ABSSSI and CABP would greatly assist in clinical trials of new antibacterial drugs to treat the 2 diseases. With a clear clinical and regulatory need for outcome measures for ABSSSI and CABP, we approached the Biomarkers Consortium of the Foundation for the National Institutes of Health about assem-bling a project team. In this issue of Clini-cal Infectious Diseases, the project team of the Biomarkers Consortium of the Foun-dation for the National Institutes o